Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
STEX
vs
S&P 500
STEX
S&P 500
Over the past 12 months, STEX has underperformed S&P 500, delivering a return of -92% compared to S&P 500's +12% growth.
Stocks Performance
STEX vs S&P 500
Performance Gap
STEX vs S&P 500
Create a free account · No card needed
Performance By Year
STEX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Biosig Technologies Inc
Glance View
Biosig Technologies is a medical technology company that builds tools for cardiac electrophysiology, the specialty that studies and treats abnormal heart rhythms. Its main product is the PURE EP system, a recording and signal-processing platform used in hospital electrophysiology labs during procedures such as mapping and ablation. The company focuses on making the heart’s electrical signals clearer so doctors can work with more usable data. Its customers are hospitals, electrophysiologists, and other medical centers that run heart-rhythm procedures. Biosig makes money by selling or licensing its system and by earning related product and service revenue tied to installations, upgrades, and support. In practice, it sits between the hospital lab and the procedure itself, supplying the hardware and software that doctors use during the case. What makes the business different is that it is not a broad medical device maker. It is concentrated on a narrow part of cardiology where signal quality matters a lot, and its value comes from capturing and processing noisy electrical data better than older recording setups. That gives it a specialized role in the workflow of electrophysiology labs rather than in everyday hospital care.